Structure via PubChem · Public domain (PubChem)
mibefradil
Sign in to saveAlso known as Ro-405967-001, Posicor
Mibefradil (trade name Posicor) was a pharmaceutical drug used for the treatment of hypertension and chronic angina pectoris. It is a nonselective calcium channel blocker. It was voluntary pulled from the market ten months after FDA approval, citing potential serious health hazards shown in post release studies.
Chemical data
- Formula
- C29H38FN3O3
- Molecular weight
- 495.6 g/mol
- IUPAC name
- [(1S,2S)-2-[2-[3-(1H-benzimidazol-2-yl)propyl-methylamino]ethyl]-6-fluoro-1-propan-2-yl-3,4-dihydro-1H-naphthalen-2-yl] 2-methoxyacetate
via PubChem
Drug data · ChEMBL
Withdrawn- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 1997
- Admin. routes
- oral
- Indications
- glioblastoma multiforme, cardiovascular disease, Central Nervous System Neoplasm
via ChEMBL · EBI
Research
935 papers- Mibefradil (posicor).Comprehensive therapy · 1997
- Clinical pharmacokinetics of mibefradil.Clinical pharmacokinetics · 1998
- Mibefradil: a selective T-type calcium antagonist.The American journal of cardiology · 1997
- Mibefradil: a new class of calcium-channel antagonists.The Annals of pharmacotherapy · 1998
- Mibefradil, a pharmacologically distinct calcium antagonist.Pharmacotherapy · 1998
via PubMed
Wikidata facts
- Mass
- 495.28972
- Has use
- medication
Show 8 more facts
- route of administration
- oral administration
- chemical formula
- C₂₉H₃₈FN₃O₃
- World Health Organisation international non-proprietary name
- mibefradil
- medical condition treated
- angina pectoris
- isomeric SMILES
- CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCCC3=NC4=CC=CC=C4N3)OC(=O)COC)C=C(C=C2)F
- canonical SMILES
- CC(C)C1C2=C(CCC1(CCN(C)CCCC3=NC4=CC=CC=C4N3)OC(=O)COC)C=C(C=C2)F
- defined daily dose
- 75
- Commons category
- Mibefradil
via Wikidata · CC0
~1 min read
Encyclopedic overview
2 sectionsContents
- Synthesis
- References
Mibefradil (trade name Posicor) was a pharmaceutical drug used for the treatment of hypertension and chronic angina pectoris. It is a nonselective calcium channel blocker. It was voluntary pulled from the market ten months after FDA approval, citing potential serious health hazards shown in post release studies.
The mechanism of action of mibefradil is characterized by the selective blockade of transient, low-voltage-activated (T-type) calcium channels over long-lasting, high-voltage-activated (L-type) calcium channels, which is probably responsible for many of its unique properties.
Excerpted from Wikipedia’s “mibefradil” article, available under the CC BY-SA 4.0 licence.